Apollo's $20B DePuy Bid Pays Less Than Half Stryker's Sales Multiple — And the Orthopedics Map Just Shifted

Bloomberg reported on Sept. 11, 2026 that Apollo Global Management is in talks to acquire Johnson & Johnson's DePuy Synthes orthopedics unit in a deal that could value the franchise at close to $20 billion. DePuy Synthes — the world's second-largest orthopedic device franchise after Stryker — generated about $9.3 billion in revenue in fiscal 2025, according to the February 2026 Bloomberg/Reuters reporting on J&J's exploration of a sale, and roughly $9.2 billion in fiscal 2024 per J&J's Oct. 14, 2025 separation announcement. Doing the math on those revenue figures: a $20 billion equity check implies a sales multiple of about 2.1x; layered with assumed debt, enterprise value lands near $28 billion, or roughly 3.0x sales.

That multiple is the headline. Stryker — the listed comp closest in scale to a standalone DePuy — trades at roughly 4.0x trailing sales on a $103.5 billion market capitalization and $25.8 billion in trailing revenue. Apollo's bid therefore pays less than half Stryker's sales multiple for a $9.3 billion-revenue business with an established hip and knee book. Zimmer Biomet trades at about 2.1x sales on $8.5 billion in trailing revenue — meaning Apollo is effectively offering DePuy at the same equity multiple as the public-market price of a smaller, slower-growing competitor.

Apollo's pitch is straightforward: underwrite a slow-growing, cash-generative orthopedic franchise at a discount to strategic comps, lever it up, squeeze operating costs, and exit in three to five years at a higher multiple. The firm reported $1.05 trillion in total AUM as of June 30, 2026, up 25% year over year, with $220 billion of asset-management inflows in the quarter alone and a record $785 million of fee-related earnings, +25% YoY. Its 2025 loan-origination volume reached $309 billion — more than any bank on Wall Street for blue-chip direct lending — so a $20 billion equity check is inside Apollo's standing capacity without forcing a fund-raise.

The broader context supports the bid. Bain's 2026 Global Healthcare Private Equity Report put 2025 healthcare PE deal value above $190 billion, the highest on record, with medtech deal value nearly doubling to about $33 billion on roughly 88 transactions. Blackstone and TPG set the template in October 2025 with the $18.3 billion take-private of Hologic at $76 per share — a roughly 46% premium to the unaffected price — and closed the deal on April 7, 2026. Apollo's DePuy offer is the second $20 billion-plus medtech take-private in nine months and confirms what Hologic suggested: large-cap orthopedic and med-tech franchises are now reachable PE assets.

The first-order competitive question is what a private-equity-owned DePuy does to share. Gabelli's April 2025 Orthopedics Market Update put DePuy Synthes at 21% share of the global hip market (behind Zimmer Biomet at 25% and Stryker at 24%) and 16% share of knees (behind Zimmer Biomet at 33% and Stryker at 29%). A cost-out mandate from Apollo — typical for a newly acquired medtech asset — typically trims R&D, sales-force footprint, and surgeon-marketing programs, which over a three-to-five-year hold tends to donate one to two points of share to the two remaining strategics.

Johnson & Johnson announced its intent to separate the orthopedics business on Oct. 14, 2025, originally as a tax-free spin-off into a standalone company called DePuy Synthes — the largest, most comprehensive orthopedics-focused company, addressing a $50 billion-plus global market and serving roughly seven million patients annually. By Feb. 19, 2026, Bloomberg reported J&J was also exploring an outright sale that could top $20 billion; the Sept. 11, 2026 Apollo talks are the resolution of that pivot. The financial logic for J&J is tight: orthopedics is J&J's slowest-growing medtech franchise, with Q2 FY2026 sales up about 5% versus cardiovascular up 12.6% in the same quarter. Selling the unit monetizes a slow-growing asset at a price Apollo can rationalize, removes roughly $9 billion of revenue that was growing below J&J's medtech average, and frees balance-sheet capacity to fund higher-growth bolt-ons in cardiovascular, robotics, and vision.

The strategic logic is even tighter. J&J's Q2 FY2026 medtech revenue of $8.4 billion already included $2.42 billion of orthopedics; if Apollo closes at $20 billion, J&J exits orthopedics at a clean cash multiple while retaining the higher-growth cardiovascular, surgery, and vision businesses. That capital can fund tuck-in M&A in Abiomed's heart-recovery franchise — where Q2 FY2026 cardiovascular sales came in below J&J's own internal expectations per MedTech Dive — and accelerate robotics investment. The alternative, a tax-free spin, would have left J&J shareholders holding a DePuy stub whose standalone cost of equity would track orthopedic multiples (Zimmer Biomet's 22.4x P/E and 12.7x EV/EBITDA), not J&J's 30.8x P/E.

Upstream, DePuy Synthes relies on a contract-manufacturing base that includes Integer Holdings (ITGR), one of the largest medical-device CDMOs and a long-running supplier of orthopedic implants and instruments. Integer itself is now being acquired by KKR for about $4.3 billion, signaling that private equity is sweeping the orthopedic supply chain alongside the OEMs. A PE-owned DePuy and a PE-owned Integer tend to negotiate from similar templates — leverage, working-capital release, multi-year supply contracts — which compresses supplier margin but locks in volume.

Downstream, the buyers are large hospital systems and ambulatory surgical centers. HCA Healthcare (HCA), the largest U.S. for-profit hospital operator, and Tenet Healthcare (THC) — whose USPI segment runs the country's largest network of ambulatory surgical centers, where the majority of outpatient joint replacements now occur — together account for a meaningful share of U.S. orthopedic implant demand. A private-equity-owned DePuy is more likely to compete aggressively on price for those ASC contracts than J&J has been as a public-company parent, which is a margin headwind for hospital purchasing groups and a tailwind for ASC throughput.

The structural question the deal raises is whether Apollo's bid marks the start of a wave. The Hologic close in April 2026, the KKR bid for Integer Holdings, and now Apollo's DePuy talks together imply that private equity is willing to underwrite the full orthopedic value chain — from contract manufacturing to OEM — at scale. For J&J, the take-private is the cleanest possible exit from its slowest-growing franchise. For Stryker and Zimmer Biomet, it is a new competitive variable: a peer that does not have to manage for quarterly EBITDA and can absorb a 200-to-300-basis-point margin reset in pursuit of share. For Apollo, it is the first $20 billion medtech franchise in its portfolio and a template for the next one.